Biosimilars – Forecast – Nephrology
In 2021, sales of erythropoiesis-stimulating agent (ESA) brands and biosimilars at the ex-manufacturer price level totaled more than $2.5 billion in the major pharmaceutical markets under study (United States, EU5, and Japan). Throughout the 2021-2031 forecast period, biosimilars of Aranesp / Nesp (darbepoetin alfa) and Mircera (methoxy polyethylene glycol-epoetin beta) will enter these markets, alongside currently available epoetin alfa biosimilars, further increasing the need for companies to set competitive pricing to either gain or maintain ESA patient shares. We present our ESA forecasts for key reference brands and their biosimilars by therapeutic area, molecule, and country / region.
Table of contents
- Biosimilars - Forecast - Nephrology
- Market forecast in the major pharmaceutical markets
- Major-market forecast: nephrology biologics (ESAs)
- Terminology
- Overarching forecast assumptions
- Overview of ESA brands in forecast
- Biosimilar entry assumptions for ESAs
- Overview of biosimilar ESA assumptions
- Overview of ESA brands in forecast
- Drug-specific forecast assumptions
- Epogen, Procrit, Eprex, Espo
- Outlook for Epogen / Procrit / Espo
- First biosimilars of ESAs in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Epogen sales forecast in the United States: 2021-2031
- Espo sales forecast in Japan: 2021-2031
- Procrit sales forecast in the United States: 2021-2031
- Eprex sales forecast in the EU5: 2021-2031
- Aranesp / Nesp
- Outlook for Aranesp / Nesp
- First biosimilars of Aranesp / Nesp in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Aranesp sales forecast in the United States: 2021-2031
- Aranesp sales forecast in the EU5: 2021-2031
- Nesp sales forecast in Japan: 2021-2031
- Mircera
- Outlook for Mircera
- First biosimilars of Mircera in the major pharmaceutical markets
- Biosimilar uptake assumptions
- Biosimilar and brand ex-manufacturer price assumptions
- Mircera sales forecast in the United States: 2021-2031
- Mircera sales forecast in the EU5: 2021-2031
- Mircera sales forecast in Japan: 2021-2031
- Epogen, Procrit, Eprex, Espo
- Market forecast in the major pharmaceutical markets
Rashi Tiwari, Pharm.D., Associate Healthcare Research and Data Analyst, Biosimilars. Prior to joining Clarivate, Dr. Tiwari was a research associate in competitive intelligence at Vyuhgenics. She earned her doctorate in pharmacy from KLE College of Pharmacy in Belagavi, where she also interned as a clinical research coordinator at KLE’s Dr. Prabhakar Kore Hospital.
Hamzah Aideed, M.Sc., is a manager on the Biosimilars team at Clarivate. His team conducts both primary and secondary market research to provide in-depth analysis and key insights into biosimilars and the biopharmaceutical industry. Previously, Mr. Aideed was a senior research executive in consulting at McCann Health, specializing in the design and execution of advanced qualitative and quantitative research methodologies for bespoke ad-hoc consulting projects. He holds an M.Sc. in biotechnology, bioprocessing, and business management from the University of Warwick and a B.Sc. in biological chemistry from Aston University in Birmingham.